These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 23808902

  • 21. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L.
    J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
    Ogata K, Mochiki E, Ojima H, Haga N, Fukuchi M, Aihara R, Ando H, Uchida N, Toyomasu Y, Suzuki M, Kimura A, Kogure N, Yokobori T, Ohno T, Kuwano H.
    J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
    [Abstract] [Full Text] [Related]

  • 24. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [Abstract] [Full Text] [Related]

  • 25. Presentation and management of gastrointestinal stromal tumours.
    Mongan AM, Malik V, Rowley S, Claxton Z, Muldoon C, O'Toole D, Ravi N, Reynolds JV.
    Ir Med J; 2013 Jun; 106(6):176-9. PubMed ID: 23909154
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL, Marchetti M, Barosi G.
    J Clin Oncol; 2007 Feb 20; 25(6):625-33. PubMed ID: 17308267
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
    Hislop J, Quayyum Z, Elders A, Fraser C, Jenkinson D, Mowatt G, Sharma P, Vale L, Petty R.
    Health Technol Assess; 2011 Jun 20; 15(25):1-178. PubMed ID: 21689502
    [Abstract] [Full Text] [Related]

  • 33. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
    Zhan WH, Wang PZ, Shao YF, Wu XT, Gu J, Li R, Wan DS, Ding KF, Shi YQ, Yu JR, Lu HS, Zou XM, Bi JW, Sun YH, Lu YF, Chen DD, Zhang XH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep 20; 9(5):383-7. PubMed ID: 17043955
    [Abstract] [Full Text] [Related]

  • 34. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
    Zuidema S, Desar IME, van Erp NP, Kievit W.
    Br J Clin Pharmacol; 2019 Sep 20; 85(9):1994-2001. PubMed ID: 31112617
    [Abstract] [Full Text] [Related]

  • 35. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
    Gronchi A.
    Eur J Cancer; 2013 Mar 20; 49(4):884-92. PubMed ID: 23206668
    [Abstract] [Full Text] [Related]

  • 36. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
    Crespo C, Pérez-Simón JA, Rodríguez JM, Sierra J, Brosa M.
    Clin Ther; 2012 Aug 20; 34(8):1774-87. PubMed ID: 22835778
    [Abstract] [Full Text] [Related]

  • 37. Surgical management of rectal gastrointestinal stromal tumors.
    Tielen R, Verhoef C, van Coevorden F, Reyners AK, van der Graaf WT, Bonenkamp JJ, van Etten B, de Wilt JH.
    J Surg Oncol; 2013 Mar 20; 107(4):320-3. PubMed ID: 22806955
    [Abstract] [Full Text] [Related]

  • 38. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.
    Ann Surg Oncol; 2007 Jan 20; 14(1):14-24. PubMed ID: 17072676
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors.
    Eisenberg BL.
    Am J Clin Oncol; 2013 Feb 20; 36(1):89-90. PubMed ID: 23334483
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.